Journal Logo

SINTILIMAB FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A MULTICENTER, SINGLE-ARM, PHASE 2 TRIAL (ORIENT-4)

S870

Tao, R.1; Fan, L.2; Song, Y.3; Hu, Y.4; Zhang, W.5; Wang, Y.6; Xu, L.7; Zhou, H.7; Li, J.2

doi: 10.1097/01.HS9.0000561760.23393.04
Simultaneous Sessions III: Aggressive lymphomas - New agents
Free

1Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

2Jiangsu Province Hospital, Nanjing

3The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou

4Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

5Peking Union Medical College Hospital, Beijing

6Tianjing Medical University Cancer Institute and Hospital, Tianjing

7Innovent Biologics (Suzhou) Co. Ltd, Suzhou, China

Back to Top | Article Outline

Background:

ENKTL account for more than 20% of the peripheral T-cell lymphoma in Asia. Patients with r/r ENKTL have a poor prognosis after failing an L-asparaginase based regimen, and the median overall survival is less than 6 months. The overexpression of PD-L1 induced by EBV infection is a potential mechanism for ENKTL to avert immune surveillance, and recent studies of PD-1 antibodies in pts with r/r ENKTL have demonstrated potential efficacy. Sintilimab, a fully human anti-PD-1 monoclonal antibody, has a safety profile consistent with other approved PD-1 antibodies and was approved for r/r classical Hodgkin lymphoma in China in 2018.

Back to Top | Article Outline

Aims:

This multicenter, single-arm, phase 2 study aims to validate the efficacy and safety of sintilimab monotherapy in patients with r/r ENKTL in China.

Back to Top | Article Outline

Methods:

Patients with pathologically confirmed r/r ENKTL were enrolled. Sintilimab was given 200 mg IV Q3W, until PD, death, unacceptable toxicity, or withdrawal from the study. Treatment beyond PD is allowed. Tumor response evaluation was performed by both PET-CT and CT/MRI with contrast. The primary endpoint was objective response rate based on LUGANO 2014 criteria. Data cut-off date for this analysis was Feb 2, 2019.

Back to Top | Article Outline

Results:

From Aug 31, 2017 to Feb 7, 2018, a total of 28 patients were enrolled: 60.7% male and the median age was 37 (range: 19˜65) yr. Sixty-eight percent of patients were stage IV and 89.3% were ECOG PS ≥ 1. All patients had failed an L-asparaginase based regimen, the median lines of previous therapy were 3 (range: 1˜13), 78.6% patients received prior radiotherapy and 7.1% had failed HSCT. Median duration of therapy was 14.04 (range: 1.4˜17.3) months and 19 patients are still receiving sintilimab. Sixty-eight percent (19/28, 95%CI: 47.6%˜84.1%) of patients achieved response (CR+PR), including 4 pts who experienced PD prior to having a response. DCR was 85.7%, including 5 pts who experienced PD before SD or response. The 1-year OS rate was 82.1% and the median OS has not been reached. Most TRAEs were G1˜2 (67.9%) and no patients discontinued treatment due to AEs. The most common TRAE was decreased lymphocyte count (46.4%) and 84.6% were grade 1˜2. SAEs occurred in 21.4% of patients and none were related to sintilimab. No patients died from AEs.

Back to Top | Article Outline

Summary/Conclusion:

Sintilimab is effective and well tolerated in r/r ENKTL and could be a promising treatment option for these patients. Early disease progression observed by PET scan in this study could be pseudo-progression as it did not correlate with poor outcome, which warrants further investigation. NCT03228836

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.